サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1511801

mRNA治療薬受託開発製造機関（CDMO）の市場規模、シェア、動向分析レポート：用途別、適応症別、最終用途別、地域別、セグメント予測、2024年～2030年

mRNA Therapeutics Contract Development & Manufacturing Organization Market Size, Share & Trends Analysis Report By Application, By Indication, By End-use, By Region, And Segment Forecasts, 2024 - 2030

出版日
ページ情報
英文 144 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
mRNA治療薬受託開発製造機関（CDMO）の市場規模、シェア、動向分析レポート：用途別、適応症別、最終用途別、地域別、セグメント予測、2024年～2030年
出版日: 2024年06月04日
発行: Grand View Research
ページ情報: 英文 144 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

mRNA治療薬受託開発製造機関（CDMO）市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、mRNA治療薬受託開発製造機関の世界市場規模は、2024年から2030年にかけて11.28%のCAGRを記録し、2030年までに83億5,000万米ドルに達すると予測されています。

mRNAや細胞送達システムの技術的進歩の高まりは、その費用対効果、製造の簡便さ、以前は治療不可能であった経路を標的とする能力と相まって、医療に革命をもたらす無限の可能性を秘めています。これは市場にとって有利な成長機会となりうる。mRNA治療薬を開発するための研究開発投資の増加と強力な製品パイプラインも、市場の成長を後押ししています。例えば、Moderna社は、2023年第4四半期の研究開発費が2022年同期比16%増の14億米ドルに達したと発表しました。

研究開発費は、同社のサイトメガロウイルス（CMV）ワクチン、RSVワクチン、COVID-19とインフルエンザに対する混合ワクチン、個別化ネオアンチゲン療法による臨床製造活動の増加によってもたらされました。このような要因がmRNA治療薬の調査努力を後押しすると予想されます。さらに、アンメットメディカルニーズに対応するための新規治療薬の開拓が、製品市場に変化をもたらしています。分子の複雑さが増すにつれ、研究および製造サービスにおける深い知識、ならびに新規分子フォーマットの持続可能な発現とスケールアップを可能にする技術の必要性が高まっています。バイオコンジュゲーションや二重特異性抗体の作製などのプラットフォーム技術は、開発期間や生産期間を大幅に短縮することが可能であり、顧客は、市場投入までの期間を短縮し、投資リスクを軽減することができる熟練したCDMOを求めています。その結果、製薬・バイオテクノロジー業界向けの商品を設計・製造するCDMOのニーズは飛躍的に高まっています。

mRNA治療薬受託開発製造機関市場レポート・ハイライト

  • ウイルスワクチン分野が2023年に100.00%のシェアで市場を独占。同分野の成長は、ウイルス感染治療用の各種ワクチンの入手可能性と発売の増加に起因している（COVID-19）。
  • 感染症分野は、感染症の罹患率の増加、従来のワクチンに対するmRNAワクチンのいくつかの利点、新たな臨床研究とパイプライン分析、製薬企業とCDMOの生産協力の増加により、2023年に最大の市場シェアを占めました。
  • バイオ企業の最終用途セグメントが市場を独占し、2023年には60.00%以上のシェアを占めました。このセグメントの成長を牽引しているのは、mRNAワクチン製造のためのCDMOとの提携・協力といった戦略的イニシアチブの増加です。
  • アジア太平洋地域は、2024年から2030年にかけて10.83%という最速の成長率を記録すると予想されています。インドや中国のような発展途上国では製薬会社や製造受託機関の数が増加しているため、アジア太平洋地域は近い将来、欧州や北米を追い抜く可能性が高いです。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 mRNA治療薬受託開発製造機関（CDMO）市場：変数、動向、範囲

  • 市場系統の見通し
  • 市場力学
  • mRNA治療薬受託開発製造機関（CDMO）市場：分析ツール
  • COVID-19の影響分析

第4章 mRNA治療薬受託開発製造機関（CDMO）市場：用途別分析

  • mRNA治療薬受託開発製造機関（CDMO）市場、用途セグメント別：主なポイント
  • mRNA治療薬受託開発製造機関（CDMO）市場：用途変動分析
  • 用途別
  • ウイルスワクチン
  • タンパク質補充療法
  • がん免疫療法

第5章 mRNA治療薬受託開発製造機関（CDMO）市場：適応症別分析

  • mRNA治療薬受託開発製造機関（CDMO）市場、適応症セグメント別：主なポイント
  • mRNA治療薬受託開発製造機関（CDMO）市場：適応症変動分析
  • 適応症別
  • 感染症
  • 代謝および遺伝性疾患
  • 心臓血管疾患および脳血管疾患

第6章 mRNA治療薬受託開発製造機関（CDMO）市場：最終用途別分析

  • mRNA治療薬受託開発製造機関（CDMO）市場、最終用途セグメント別：主なポイント
  • mRNA治療薬受託開発製造機関（CDMO）市場：最終用途変動分析
  • 最終用途別
  • バイオテクノロジー企業
  • 製薬会社
  • 政府および学術研究機関

第7章 mRNA治療薬受託開発製造機関（CDMO）市場：地域別分析

  • mRNA治療薬受託開発製造機関（CDMO）市場、地域セグメント別：主なポイント
  • mRNA治療薬受託開発製造機関（CDMO）市場シェア分析、2023年および2030年
  • 地域別
  • 北米
  • 欧州
  • アジア太平洋地域
  • ラテンアメリカ
  • 中東・アフリカ

第8章 mRNA治療薬受託開発製造機関（CDMO）市場：競合情勢

  • 市場参入企業の分類
  • 市況分析、2022/2023年（ヒートマップ分析）
  • 企業プロファイル
  • ベンダー情勢
  • 主要企業の市場シェア分析、2023年
  • Danaher (Aldevron)
  • Biomay AG
  • Bio-Synthesis, Inc.
  • eTheRNA
  • Kaneka Eurogentec S.A.
  • TriLink BioTechnologies
  • ApexBio Technology
  • BioNTech SE
  • BioCina
  • Lonza
  • Recipharm AB
  • Novo Holdings (Catalent, Inc.)
  • Samsung Biologics
図表

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by application, 2018 - 2030 (USD Million)
  • Table 4 North America mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by indication, 2018 - 2030 (USD Million)
  • Table 5 North America mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by end-use, 2018 - 2030 (USD Million)
  • Table 6 U.S. mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by application, 2018 - 2030 (USD Million)
  • Table 7 U.S. mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by indication, 2018 - 2030 (USD Million)
  • Table 8 U.S. mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by end-use, 2018 - 2030 (USD Million)
  • Table 9 Canada mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by application, 2018 - 2030 (USD Million)
  • Table 10 Canada mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by indication, 2018 - 2030 (USD Million)
  • Table 11 Canada mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by end-use, 2018 - 2030 (USD Million)
  • Table 12 Europe mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by region, 2018 - 2030 (USD Million)
  • Table 13 Europe mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by application, 2018 - 2030 (USD Million)
  • Table 14 Europe mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by indication, 2018 - 2030 (USD Million)
  • Table 15 Europe mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by end-use, 2018 - 2030 (USD Million)
  • Table 16 UK mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by application, 2018 - 2030 (USD Million)
  • Table 17 UK mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by indication, 2018 - 2030 (USD Million)
  • Table 18 UK mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by end-use, 2018 - 2030 (USD Million)
  • Table 19 Germany mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by application, 2018 - 2030 (USD Million)
  • Table 20 Germany mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by indication, 2018 - 2030 (USD Million)
  • Table 21 Germany mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by end-use, 2018 - 2030 (USD Million)
  • Table 22 France mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by application, 2018 - 2030 (USD Million)
  • Table 23 France mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by indication, 2018 - 2030 (USD Million)
  • Table 24 France mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by end-use, 2018 - 2030 (USD Million)
  • Table 25 Italy mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by application, 2018 - 2030 (USD Million)
  • Table 26 Italy mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by indication, 2018 - 2030 (USD Million)
  • Table 27 Italy mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by end-use, 2018 - 2030 (USD Million)
  • Table 28 Spain mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by application, 2018 - 2030 (USD Million)
  • Table 29 Spain mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by indication, 2018 - 2030 (USD Million)
  • Table 30 Spain mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by end-use, 2018 - 2030 (USD Million)
  • Table 31 Sweden mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by application, 2018 - 2030 (USD Million)
  • Table 32 Sweden mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by indication, 2018 - 2030 (USD Million)
  • Table 33 Sweden mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by end-use, 2018 - 2030 (USD Million)
  • Table 34 Denmark mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by application, 2018 - 2030 (USD Million)
  • Table 35 Denmark mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by indication, 2018 - 2030 (USD Million)
  • Table 36 Denmark mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by end-use, 2018 - 2030 (USD Million)
  • Table 37 Norway mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by application, 2018 - 2030 (USD Million)
  • Table 38 Norway mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by indication, 2018 - 2030 (USD Million)
  • Table 39 Norway mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by end-use, 2018 - 2030 (USD Million)
  • Table 40 Asia Pacific mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by region, 2018 - 2030 (USD Million)
  • Table 41 Asia Pacific mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by application, 2018 - 2030 (USD Million)
  • Table 42 Asia Pacific mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by indication, 2018 - 2030 (USD Million)
  • Table 43 Asia Pacific mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by end-use, 2018 - 2030 (USD Million)
  • Table 44 Japan mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by application, 2018 - 2030 (USD Million)
  • Table 45 Japan mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by indication, 2018 - 2030 (USD Million)
  • Table 46 Japan mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by end-use, 2018 - 2030 (USD Million)
  • Table 47 China mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by application, 2018 - 2030 (USD Million)
  • Table 48 China mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by indication, 2018 - 2030 (USD Million)
  • Table 49 China mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by end-use, 2018 - 2030 (USD Million)
  • Table 50 India mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by application, 2018 - 2030 (USD Million)
  • Table 51 India mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by indication, 2018 - 2030 (USD Million)
  • Table 52 India mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by end-use, 2018 - 2030 (USD Million)
  • Table 53 South Korea mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by application, 2018 - 2030 (USD Million)
  • Table 54 South Korea mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by indication, 2018 - 2030 (USD Million)
  • Table 55 South Korea mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by end-use, 2018 - 2030 (USD Million)
  • Table 56 Australia mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by application, 2018 - 2030 (USD Million)
  • Table 57 Australia mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by indication, 2018 - 2030 (USD Million)
  • Table 58 Australia mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by end-use, 2018 - 2030 (USD Million)
  • Table 59 Indonesia mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by application, 2018 - 2030 (USD Million)
  • Table 60 Indonesia mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by indication, 2018 - 2030 (USD Million)
  • Table 61 Indonesia mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by end-use, 2018 - 2030 (USD Million)
  • Table 62 Latin America mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by region, 2018 - 2030 (USD Million)
  • Table 63 Latin America mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by application, 2018 - 2030 (USD Million)
  • Table 64 Latin America mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by indication, 2018 - 2030 (USD Million)
  • Table 65 Latin America mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by end-use, 2018 - 2030 (USD Million)
  • Table 66 Brazil mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by application, 2018 - 2030 (USD Million)
  • Table 67 Brazil mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by indication, 2018 - 2030 (USD Million)
  • Table 68 Brazil mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by end-use, 2018 - 2030 (USD Million)
  • Table 69 Mexico mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by application, 2018 - 2030 (USD Million)
  • Table 70 Mexico mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by indication, 2018 - 2030 (USD Million)
  • Table 71 Mexico mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by end-use, 2018 - 2030 (USD Million)
  • Table 72 Argentina mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by application, 2018 - 2030 (USD Million)
  • Table 73 Argentina mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by indication, 2018 - 2030 (USD Million)
  • Table 74 Argentina mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by end-use, 2018 - 2030 (USD Million)
  • Table 75 MEA mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by region, 2018 - 2030 (USD Million)
  • Table 76 MEA mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by application, 2018 - 2030 (USD Million)
  • Table 77 MEA mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by indication, 2018 - 2030 (USD Million)
  • Table 78 MEA mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by end-use, 2018 - 2030 (USD Million)
  • Table 79 South Africa mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by application, 2018 - 2030 (USD Million)
  • Table 80 South Africa mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by indication, 2018 - 2030 (USD Million)
  • Table 81 South Africa mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by end-use, 2018 - 2030 (USD Million)
  • Table 82 Saudi Arabia mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by application, 2018 - 2030 (USD Million)
  • Table 83 Saudi Arabia mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by indication, 2018 - 2030 (USD Million)
  • Table 84 Saudi Arabia mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by end-use, 2018 - 2030 (USD Million)
  • Table 85 UAE mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by application, 2018 - 2030 (USD Million)
  • Table 86 UAE mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by indication, 2018 - 2030 (USD Million)
  • Table 87 UAE mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by end-use, 2018 - 2030 (USD Million)
  • Table 88 Kuwait mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by application, 2018 - 2030 (USD Million)
  • Table 89 Kuwait mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by indication, 2018 - 2030 (USD Million)
  • Table 90 Kuwait mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by end-use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 mRNA therapeutics contract development & manufacturing organization (CDMO) market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Data analysis models
  • Fig. 5 Market formulation and validation
  • Fig. 6 Data validating & publishing
  • Fig. 7 Commodity flow analysis
  • Fig. 8 Market snapshot
  • Fig. 9 Segment snapshot
  • Fig. 10 Segment snapshot
  • Fig. 11 Competitive landscape snapshot
  • Fig. 12 Parent market outlook, 2023 (USD Billion)
  • Fig. 13 Ancillary market outlook, 2023 (USD Billion)
  • Fig. 14 mRNA therapeutics contract development & manufacturing organization (CDMO) market dynamics
  • Fig. 15 Porter's five forces analysis
  • Fig. 16 PESTEL analysis
  • Fig. 17 mRNA therapeutics contract development & manufacturing organization (CDMO) market: Application outlook and key takeaways
  • Fig. 18 mRNA therapeutics contract development & manufacturing organization (CDMO) market: Application movement analysis
  • Fig. 19 Viral vaccines market estimates and forecast, 2021 - 2030 (USD Million)
  • Fig. 20 Protein replacement therapies market estimates and forecast, 2021 - 2030 (USD Million)
  • Fig. 21 Cancer immunotherapies market estimates and forecast, 2021 - 2030 (USD Million)
  • Fig. 22 mRNA therapeutics contract development & manufacturing organization (CDMO) market: Indication outlook and key takeaways
  • Fig. 23 mRNA therapeutics contract development & manufacturing organization (CDMO) market: Indication movement analysis
  • Fig. 24 Infectious diseases market estimates and forecast, 2021 - 2030 (USD Million)
  • Fig. 25 Metabolic & genetic diseases market estimates and forecast, 2021 - 2030 (USD Million)
  • Fig. 26 Cardiovascular & cerebrovascular diseases market estimates and forecast, 2021 - 2030 (USD Million)
  • Fig. 27 mRNA therapeutics contract development & manufacturing organization (CDMO) market: End use outlook and key takeaways
  • Fig. 28 mRNA therapeutics contract development & manufacturing organization (CDMO) market: End use movement analysis
  • Fig. 29 Biotech companies market estimates and forecast, 2021 - 2030 (USD Million)
  • Fig. 30 Pharmaceutical companies market estimates and forecast, 2021 - 2030 (USD Million)
  • Fig. 31 Government & academic research institutes market estimates and forecast, 2021 - 2030 (USD Million)
  • Fig. 32 Regional market: Key takeaways
  • Fig. 33 Regional outlook, 2023 & 2030
  • Fig. 34 Regional outlook, 2023 & 2030
  • Fig. 35 North America mRNA therapeutics contract development & manufacturing organization (CDMO) market estimates and forecasts, 2021 - 2030 (USD Million)
  • Fig. 36 Key country dynamics
  • Fig. 37 U.S. mRNA therapeutics contract development & manufacturing organization (CDMO) market estimates and forecasts, 2021 - 2030 (USD Million)
  • Fig. 38 Key country dynamics
  • Fig. 39 Canada mRNA therapeutics contract development & manufacturing organization (CDMO) market estimates and forecasts, 2021 - 2030 (USD Million)
  • Fig. 40 Europe mRNA therapeutics contract development & manufacturing organization (CDMO) market estimates and forecasts, 2021 - 2030 (USD Million)
  • Fig. 41 Key country dynamics
  • Fig. 42 UK mRNA therapeutics contract development & manufacturing organization (CDMO) market estimates and forecasts, 2021 - 2030 (USD Million)
  • Fig. 43 Key country dynamics
  • Fig. 44 Germany mRNA therapeutics contract development & manufacturing organization (CDMO) market estimates and forecasts, 2021 - 2030 (USD Million)
  • Fig. 45 Key country dynamics
  • Fig. 46 France mRNA therapeutics contract development & manufacturing organization (CDMO) market estimates and forecasts, 2021 - 2030 (USD Million)
  • Fig. 47 Key country dynamics
  • Fig. 48 Italy mRNA therapeutics contract development & manufacturing organization (CDMO) market estimates and forecasts, 2021 - 2030 (USD Million)
  • Fig. 49 Key country dynamics
  • Fig. 50 Spain mRNA therapeutics contract development & manufacturing organization (CDMO) market estimates and forecasts, 2021 - 2030 (USD Million)
  • Fig. 51 Key country dynamics
  • Fig. 52 Denmark mRNA therapeutics contract development & manufacturing organization (CDMO) market estimates and forecasts, 2021 - 2030 (USD Million)
  • Fig. 53 Key country dynamics
  • Fig. 54 Sweden mRNA therapeutics contract development & manufacturing organization (CDMO) market estimates and forecasts, 2021 - 2030 (USD Million)
  • Fig. 55 Key country dynamics
  • Fig. 56 Norway mRNA therapeutics contract development & manufacturing organization (CDMO) market estimates and forecasts, 2021 - 2030 (USD Million)
  • Fig. 57 Asia Pacific mRNA therapeutics contract development & manufacturing organization (CDMO) market estimates and forecasts, 2021 - 2030 (USD Million)
  • Fig. 58 Key country dynamics
  • Fig. 59 Japan mRNA therapeutics contract development & manufacturing organization (CDMO) market estimates and forecasts, 2021 - 2030 (USD Million)
  • Fig. 60 Key country dynamics
  • Fig. 61 China mRNA therapeutics contract development & manufacturing organization (CDMO) market estimates and forecasts, 2021 - 2030 (USD Million)
  • Fig. 62 Key country dynamics
  • Fig. 63 India mRNA therapeutics contract development & manufacturing organization (CDMO) market estimates and forecasts, 2021 - 2030 (USD Million)
  • Fig. 64 Key country dynamics
  • Fig. 65 Australia mRNA therapeutics contract development & manufacturing organization (CDMO) market estimates and forecasts, 2021 - 2030 (USD Million)
  • Fig. 66 Key country dynamics
  • Fig. 67 South Korea mRNA therapeutics contract development & manufacturing organization (CDMO) market estimates and forecasts, 2021 - 2030 (USD Million)
  • Fig. 68 Key country dynamics
  • Fig. 69 Indonesia mRNA therapeutics contract development & manufacturing organization (CDMO) market estimates and forecasts, 2021 - 2030 (USD Million)
  • Fig. 70 Latin America mRNA therapeutics contract development & manufacturing organization (CDMO) market estimates and forecasts, 2021 - 2030 (USD Million)
  • Fig. 71 Key country dynamics
  • Fig. 72 Brazil mRNA therapeutics contract development & manufacturing organization (CDMO) market estimates and forecasts, 2021 - 2030 (USD Million)
  • Fig. 73 Key country dynamics
  • Fig. 74 Mexico mRNA therapeutics contract development & manufacturing organization (CDMO) market estimates and forecasts, 2021 - 2030 (USD Million)
  • Fig. 75 Key country dynamics
  • Fig. 76 Argentina mRNA therapeutics contract development & manufacturing organization (CDMO) market estimates and forecasts, 2021 - 2030 (USD Million)
  • Fig. 77 MEA mRNA therapeutics contract development & manufacturing organization (CDMO) market estimates and forecasts, 2021 - 2030 (USD Million)
  • Fig. 78 Key country dynamics
  • Fig. 79 South Africa mRNA therapeutics contract development & manufacturing organization (CDMO) market estimates and forecasts, 2021 - 2030 (USD Million)
  • Fig. 80 Key country dynamics
  • Fig. 81 Saudi Arabia mRNA therapeutics contract development & manufacturing organization (CDMO) market estimates and forecasts, 2021 - 2030 (USD Million)
  • Fig. 82 Key country dynamics
  • Fig. 83 UAE mRNA therapeutics contract development & manufacturing organization (CDMO) market estimates and forecasts, 2021 - 2030 (USD Million)
  • Fig. 84 Key country dynamics
  • Fig. 85 Kuwait mRNA therapeutics contract development & manufacturing organization (CDMO) market estimates and forecasts, 2021 - 2030 (USD Million)
  • Fig. 86 Market participant categorization
  • Fig. 87 Heat map analysis
  • Fig. 88 Strategy mapping
目次
Product Code: GVR-4-68040-083-7

mRNA Therapeutics Contract Development & Manufacturing Organization Market Growth & Trends:

The global mRNA therapeutics contract development & manufacturing organization market size is expected to reach USD 8.35 billion by 2030, registering a CAGR of 11.28% from 2024 to 2030, according to a new report by Grand View Research, Inc. Growing technological advancements in mRNA and cellular delivery systems, coupled with their cost effectiveness, manufacturing simplicity, and ability to target previously undruggable pathways, have limitless potential to revolutionize medicine. This could represent lucrative growth opportunities for the market. Increasing R&D investments to develop mRNA therapeutics and a strong product pipeline are also propelling the market's growth. For instance, Moderna shared that R&D expenses for the fourth quarter of 2023 increased by 16% to USD 1.4 billion compared to the same quarter of 2022.

The R&D spending was driven by increased clinical manufacturing activities, with the company's Cytomegalovirus (CMV) vaccine, RSV vaccine, and combination vaccine against COVID-19 & flu, as well as its individualized neoantigen therapy. Such factors are expected to boost research efforts in mRNA therapeutics. In addition, developing novel therapeutics to address unmet medical needs is altering the product market. The rise in molecular complexity drives the need for in-depth knowledge in research and manufacturing services, as well as the technology to enable sustainable expression and scale-up of novel molecular formats. Platform technologies, such as those for bioconjugation or the creation of bispecific antibodies, can drastically shorten development and production times, and customers are looking for skilled CDMOs who can assist them shorten the time to market and reducing investment risk. Consequently, the need for CDMOs to design and produce goods for the pharmaceutical and biotechnology industries is growing exponentially.

mRNA Therapeutics Contract Development & Manufacturing Organization Market Report Highlights:

  • The viral vaccines segment dominated the market with a share of 100.00% in 2023. Growth in the segment can be attributed to the rising availability and launch of various vaccines for the treatment of viral infection (COVID-19)
  • The infectious diseases segment held the largest market share in 2023 due to the growing incidence of infectious diseases, several advantages of mRNA vaccine over conventional vaccines, emerging clinical studies & pipeline analysis, and increasing collaboration between pharmaceutical companies & CDMO for production
  • The biotech companies end-use segment dominated the market and accounted for a share of more than 60.00% in 2023. The segment growth is driven by increasing strategic initiatives, such as partnerships & collaborations with CDMOs, to manufacture mRNA vaccines
  • Asia Pacific is expected to register the fastest growth rate of 10.83% from 2024 to 2030. Due to the rising number of pharmaceutical companies and contract manufacturing organizations in developing countries like India and China, Asia Pacific is likely to overtake Europe and North America in the near future

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market Segmentation and Scope
    • 1.1.1 Regional Scope
  • 1.2 Estimates And Forecast Timeline
  • 1.3 Market Definition
  • 1.4 Research Methodology
  • 1.5 Information Procurement
    • 1.5.1 Information Analysis
    • 1.5.2 Market Formulation & Data Visualization
    • 1.5.3 Data Validation & Publishing
  • 1.6 Research Scope And Assumptions
    • 1.6.1 Commodity Flow Analysis
    • 1.6.2 Top Down Market Estimation
    • 1.6.3 Region/Country Based Segment Share Calculation.
    • 1.6.4 Multivariate Analysis
    • 1.6.5 Mrna Therapeutics Contract Development & Manufacturing Organization (CDMO) Market: CAGR Calculation
  • 1.7 List of Secondary Sources
  • 1.8 List of Abbreviations

Chapter 2 Executive Summary

  • 2.1 Market Snapshot
  • 2.2 Segment Snapshot
  • 2.3 Segment Snapshot
  • 2.4 Competitive Landscape Snapshot

Chapter 3 mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market: Variables, Trends, & Scope

  • 3.1 Market Lineage Outlook
    • 3.1.1 Parent Market Outlook
    • 3.1.2 Ancillary Market Outlook
      • 3.1.2.1 Global Recombinant Protein Therapeutics CDMO Market
  • 3.2 Market Dynamics
    • 3.2.1 Market Driver Analysis
      • 3.2.1.1 Rapid Adoption Of Mrna In Vaccine Development
      • 3.2.1.2 Multiple Research Efforts On Mrna Therapeutics
      • 3.2.1.3 Major Funding For Mrna Research
    • 3.2.2 Market Restraint Analysis
      • 3.2.2.1 Availability of Low-cost Substitute Therapies
      • 3.2.2.2 High Research Cost
  • 3.3 mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market: Analysis Tools
    • 3.3.1 Porter's Five Forces Analysis
    • 3.3.2 Pestel Analysis
  • 3.4 COVID-19 Impact Analysis

Chapter 4 mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market: Application Analysis

  • 4.1 mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market by Application Segment: Key Takeaways
  • 4.2 mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market: Application Movement Analysis
  • 4.3 mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates & Forecast by Application (USD Million)
  • 4.4 Viral Vaccines
    • 4.4.1 Viral Vaccines Market, 2018 - 2030 (USD Million)
  • 4.5 Protein Replacement Therapies
    • 4.5.1 Protein Replacement Therapies Market, 2018 - 2030 (USD Million)
  • 4.6 Cancer Immunotherapies
    • 4.6.1 Cancer Immunotherapies Market, 2018 - 2030 (USD Million)

Chapter 5 mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market: Indication Analysis

  • 5.1 mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market by Indication Segment: Key Takeaways
  • 5.2 mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market: Indication Movement Analysis
  • 5.3 mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates & Forecast by Indication (USD Million)
  • 5.4 Infectious Diseases
    • 5.4.1 Infectious Diseases Market, 2018 - 2030 (USD Million)
  • 5.5 Metabolic & Genetic Diseases
    • 5.5.1 Metabolic & Genetic Diseases Market, 2018 - 2030 (USD Million)
  • 5.6 Cardiovascular & Cerebrovascular Diseases
    • 5.6.1 Cardiovascular & Cerebrovascular Diseases Market, 2018 - 2030 (USD Million)

Chapter 6 mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market: End-use Analysis

  • 6.1 mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market by End-use Segment: Key Takeaways
  • 6.2 mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market: End-use Movement Analysis
  • 6.3 mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates & Forecast by End-use (USD Million)
  • 6.4 Biotech Companies
    • 6.4.1 Biotech Companies Market, 2018 - 2030 (USD Million)
  • 6.5 Pharmaceutical Companies
    • 6.5.1 Pharmaceutical Companies Market, 2018 - 2030 (USD Million)
  • 6.6 Government & Academic Research Institutes
    • 6.6.1 Government & Academic Research Institutes Market, 2018 - 2030 (USD Million)

Chapter 7 mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market: Regional Analysis

  • 7.1 mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market by Regional Segment: Key Takeaways
  • 7.2 mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO): Market Share Analysis, 2023 & 2030
  • 7.3 mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO): Market Estimates and Forecast, by Region (USD Million)
  • 7.4 North America
    • 7.4.1 North America Mrna Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021 - 2030 (USD Million)
    • 7.4.2 U.S.
      • 7.4.2.1 Key Country Dynamics
      • 7.4.2.2 Competitive Scenario
      • 7.4.2.3 U.S. mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021 - 2030 (USD Million)
    • 7.4.3 Canada
      • 7.4.3.1 Key Country Dynamics
      • 7.4.3.2 Competitive Scenario
      • 7.4.3.3 Canada mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021 - 2030 (USD Million)
  • 7.5 Europe
    • 7.5.1 Europe Mrna Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021 - 2030 (USD Million)
    • 7.5.2 UK
      • 7.5.2.1 Key Country Dynamics
      • 7.5.2.2 Competitive Scenario
      • 7.5.2.3 UK mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021 - 2030 (USD Million)
    • 7.5.3 Germany
      • 7.5.3.1 Key Country Dynamics
      • 7.5.3.2 Competitive Scenario
      • 7.5.3.3 Germany mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021 - 2030 (USD Million)
    • 7.5.4 France
      • 7.5.4.1 Key Country Dynamics
      • 7.5.4.2 Competitive Scenario
      • 7.5.4.3 France mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021 - 2030 (USD Million)
    • 7.5.5 Italy
      • 7.5.5.1 Key Country Dynamics
      • 7.5.5.2 Competitive Scenario
      • 7.5.5.3 Italy mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021 - 2030 (USD Million)
    • 7.5.6 Spain
      • 7.5.6.1 Key Country Dynamics
      • 7.5.6.2 Competitive Scenario
      • 7.5.6.3 Spain mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021 - 2030 (USD Million)
    • 7.5.7 Denmark
      • 7.5.7.1 Key Country Dynamics
      • 7.5.7.2 Competitive Scenario
      • 7.5.7.3 Denmark mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021 - 2030 (USD Million)
    • 7.5.8 Sweden
      • 7.5.8.1 Competitive Scenario
      • 7.5.8.2 Key Country Dynamics
      • 7.5.8.3 Sweden mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021 - 2030 (USD Million)
    • 7.5.9 Norway
      • 7.5.9.1 Key Country Dynamics
      • 7.5.9.2 Competitive Scenario
      • 7.5.9.3 Norway mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021 - 2030 (USD Million)
  • 7.6 Asia Pacific
    • 7.6.1 Asia Pacific Mrna Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021 - 2030 (Usd Million
    • 7.6.2 Japan
      • 7.6.2.1 Key Country Dynamics
      • 7.6.2.2 Competitive Scenario
      • 7.6.2.3 Japan Mrna Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021 - 2030 (USD Million)
    • 7.6.3 China
      • 7.6.3.1 Key Country Dynamics
      • 7.6.3.2 Competitive Scenario
      • 7.6.3.3 China Mrna Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021 - 2030 (USD Million)
    • 7.6.4 India
      • 7.6.4.1 Key Country Dynamics
      • 7.6.4.2 Competitive Scenario
      • 7.6.4.3 India Mrna Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021 - 2030 (USD Million)
    • 7.6.5 Australia
      • 7.6.5.1 Key Country Dynamics
      • 7.6.5.2 Competitive Scenario
      • 7.6.5.3 Australia Mrna Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021 - 2030 (USD Million)
    • 7.6.6 South Korea
      • 7.6.6.1 Key Country Dynamics
      • 7.6.6.2 Competitive Scenario
      • 7.6.6.3 South Korea Mrna Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021 - 2030 (USD Million)
    • 7.6.7 Indonesia
      • 7.6.7.1 Key Country Dynamics
      • 7.6.7.2 Competitive Scenario
      • 7.6.7.3 Indonesia Mrna Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021 - 2030 (USD Million)
  • 7.7 Latin America
    • 7.7.1 Latin America Mrna Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021 - 2030 (USD Million)
    • 7.7.2 Brazil
      • 7.7.2.1 Key Country Dynamics
      • 7.7.2.2 Competitive Scenario
      • 7.7.2.3 Brazil Mrna Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021 - 2030 (USD Million)
    • 7.7.3 Mexico
      • 7.7.3.1 Key Country Dynamics
      • 7.7.3.2 Competitive Scenario
      • 7.7.3.3 Mexico Mrna Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021 - 2030 (USD Million)
    • 7.7.4 Argentina
      • 7.7.4.1 Key Country Dynamics
      • 7.7.4.2 Competitive Scenario
      • 7.7.4.3 Argentina mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021 - 2030 (USD Million)
  • 7.8 MEA
    • 7.8.1 Mea Mrna Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021 - 2030 (USD Million)
    • 7.8.2 South Africa
      • 7.8.2.1 Key Country Dynamics
      • 7.8.2.2 Competitive Scenario
    • 7.8.3 Saudi Arabia
      • 7.8.3.1 Key Country Dynamics
      • 7.8.3.2 Competitive Scenario
      • 7.8.3.3 Saudi Arabia mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021 - 2030 (USD Million)
    • 7.8.4 UAE
      • 7.8.4.1 Key Country Dynamics
      • 7.8.4.2 Competitive Scenario
      • 7.8.4.3 UAE mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021 - 2030 (USD Million)
    • 7.8.5 Kuwait
      • 7.8.5.1 Key Country Dynamics
      • 7.8.5.2 Competitive Scenario
      • 7.8.5.3 Kuwait mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021 - 2030 (USD Million)

Chapter 8 mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market: Competitive Landscape

  • 8.1. Market Participant Categorization
  • 8.2. Market Position Analysis, 2022/2023 (Heat Map Analysis)
  • 8.3. Company Profiles
    • 8.3.1. Strategy Mapping
    • 8.3.2. Service Launches
    • 8.3.3. Acquisition
    • 8.3.4. Partnerships/Agreements/Collaboration
    • 8.3.5. Expansions
  • 8.4. Vendor Landscape
    • 8.4.1. Key company market share analysis, 2023
    • 8.4.2. Danaher (Aldevron)
      • 8.4.2.1. Company overview
      • 8.4.2.2. Financial performance
      • 8.4.2.3. Product/service benchmarking
      • 8.4.2.4. Strategic initiatives
    • 8.4.3. Biomay AG
      • 8.4.3.1. Company overview
      • 8.4.3.2. Financial performance
      • 8.4.3.3. Product/service benchmarking
      • 8.4.3.4. Strategic initiatives
    • 8.4.4. Bio-Synthesis, Inc.
      • 8.4.4.1. Company overview
      • 8.4.4.2. Financial performance
      • 8.4.4.3. Product/service benchmarking
      • 8.4.4.4. Strategic initiatives
    • 8.4.5. eTheRNA
      • 8.4.5.1. Company overview
      • 8.4.5.2. Financial performance
      • 8.4.5.3. Product/service benchmarking
      • 8.4.5.4. Strategic initiatives
    • 8.4.6. Kaneka Eurogentec S.A.
      • 8.4.6.1. Company overview
      • 8.4.6.2. Financial performance
      • 8.4.6.3. Product/service benchmarking
      • 8.4.6.4. Strategic initiatives
    • 8.4.7. TriLink BioTechnologies
      • 8.4.7.1. Company overview
      • 8.4.7.2. Financial performance
      • 8.4.7.3. Product/service benchmarking
      • 8.4.7.4. Strategic initiatives
    • 8.4.8. ApexBio Technology
      • 8.4.8.1. Company overview
      • 8.4.8.2. Financial performance
      • 8.4.8.3. Product/service benchmarking
      • 8.4.8.4. Strategic initiatives
    • 8.4.9. BioNTech SE
      • 8.4.9.1. Company overview
      • 8.4.9.2. Financial performance
      • 8.4.9.3. Product/service benchmarking
      • 8.4.9.4. Strategic initiatives
    • 8.4.10. BioCina
      • 8.4.10.1. Company overview
      • 8.4.10.2. Financial performance
      • 8.4.10.3. Product/service benchmarking
      • 8.4.10.4. Strategic initiatives
    • 8.4.11. Lonza
      • 8.4.11.1. Company overview
      • 8.4.11.2. Financial performance
      • 8.4.11.3. Product/service benchmarking
      • 8.4.11.4. Strategic initiatives
    • 8.4.12. Recipharm AB
      • 8.4.12.1. Company overview
      • 8.4.12.2. Financial performance
      • 8.4.12.3. Product/service benchmarking
      • 8.4.12.4. Strategic initiatives
    • 8.4.13. Novo Holdings (Catalent, Inc.)
      • 8.4.13.1. Company overview
      • 8.4.13.2. Financial performance
      • 8.4.13.3. Product/service benchmarking
      • 8.4.13.4. Strategic initiatives
    • 8.4.14. Samsung Biologics
      • 8.4.14.1. Company overview
      • 8.4.14.2. Financial performance
      • 8.4.14.3. Product/service benchmarking
      • 8.4.14.4. Strategic initiatives